RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

This study is testing whether combining a standard lung cancer immunotherapy drug (durvalumab) with chemotherapy and a new drug that activates the immune system (RMT) works better than the standard treatment alone for advanced non-small cell lung cancer (a type of lung cancer called adenocarcinoma). **You may be eligible if...** - You have been diagnosed with advanced or metastatic lung adenocarcinoma (stages IIIB/C or IV) - Your tumour does not have certain genetic changes (EGFR, ALK, ROS1, and some others) that would direct you to targeted therapies - You are reasonably active (ECOG 0 or 1) - You weigh more than 30 kg - Your organs are functioning adequately **You may NOT be eligible if...** - You have already received systemic treatment (chemotherapy or immunotherapy) for advanced/metastatic lung cancer - Your tumour has EGFR, ALK, or ROS1 mutations that have standard targeted therapies available - You have brain metastases that are unstable or require high-dose steroids Talk to your doctor to see if this trial is right for you.